Brown & Williamson Tobacco Corp. v. FDA

Brown & Williamson Tobacco Corp. v. FDA
Case name	Brown & Williamson Tobacco Corp. v. FDA
Citation	529 U.S. 120 (2000)
Decided	March 21, 2000
Docket	No. 99-159
Prior	Tobacco Institute, Inc. v. Food and Drug Administration, 183 F.3d 155 (D.C. Cir. 1999)
Holding	FDA lacks authority under the Federal Food, Drug, and Cosmetic Act to regulate tobacco products as "drugs" or "devices"
Majority	Rehnquist
Joinmajority	O'Connor, Scalia, Kennedy, Thomas
Concurrence	Stevens (in judgment)
Dissent	Souter (joined by Ginsburg)
Laws applied	Federal Food, Drug, and Cosmetic Act

Brown & Williamson Tobacco Corp. v. FDA

Brown & Williamson Tobacco Corp. v. FDA was a landmark Supreme Court case resolving whether the Food and Drug Administration could regulate tobacco products under the Federal Food, Drug, and Cosmetic Act; the Court held that the FDA lacked such authority, shaping federal regulatory policy on tobacco and influencing litigation involving the Centers for Disease Control and Prevention, Department of Health and Human Services, and public health advocacy groups. The decision, written by Chief Justice William Rehnquist, intersected with precedents from the Administrative Procedure Act, decisions of the United States Court of Appeals for the District of Columbia Circuit, and ongoing debates in Congress over regulatory jurisdiction and consumer protection.

Background

The dispute arose from petitions by public health organizations and rulings by the Food and Drug Administration about whether nicotine delivery systems and cigarettes could be regulated as "drugs" or "devices" under the Federal Food, Drug, and Cosmetic Act. Parties included major industry actors such as Brown & Williamson Tobacco Corporation, Philip Morris USA, and trade associations like the Tobacco Institute, alongside government entities including the Department of Health and Human Services and advocacy organizations such as the American Cancer Society and American Medical Association. Scientific evidence and reports from the Surgeon General and the Institute of Medicine framed the health context, while legislative activity in the United States Congress and pending statutes influenced administrative action.

Procedural History

After FDA officials issued notices and proposed regulations regarding nicotine and cigarette labeling and distribution, tobacco companies and the Tobacco Institute sought review in the United States Court of Appeals for the District of Columbia Circuit. The D.C. Circuit remanded certain matters but left intact the FDA's assertion of jurisdiction in part, prompting certiorari to the Supreme Court of the United States. Amicus briefs were filed by entities including the American Heart Association, State of New York, and various industry groups. The case presented questions of statutory interpretation under the Federal Food, Drug, and Cosmetic Act and doctrines articulated in precedent cases such as Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc. and Massachusetts v. Environmental Protection Agency (though the latter postdates the decision, similar administrative law principles framed argumentation).

Supreme Court Decision

In a 5–4 decision, Chief Justice William Rehnquist delivered the opinion for the Court, concluding that Congress had not granted the Food and Drug Administration authority to regulate tobacco as a "drug" or "device" under the Federal Food, Drug, and Cosmetic Act. Justice John Paul Stevens concurred in the judgment but disagreed with aspects of the majority's statutory analysis; Justice David Souter wrote a dissent joined by Justice Ruth Bader Ginsburg. The Court examined statutory text, legislative history including hearings before the Senate Committee on Labor and Human Resources and the House Committee on Energy and Commerce, and the practical consequences of treating cigarettes as regulated products under the FDCA.

Legal Reasoning and Holdings

The majority applied principles of statutory construction and administrative deference, referencing the framework from Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc. to assess the Food and Drug Administration's interpretation, but ultimately relied on Congress's expressions about tobacco in statutes and reports including actions by the Congressional Research Service. The Court emphasized that reading the FDCA to cover tobacco would produce "absurd results" given Congress's longstanding regulatory treatment of tobacco under statutes like the Federal Cigarette Labeling and Advertising Act and appropriations riders enacted by the United States Congress. The Court held that the FDA's asserted jurisdiction was inconsistent with the statutory scheme and congressional intent, and that agency action attempting broad regulation of nicotine and cigarette design exceeded the FDA's delegated powers.

Impact and Aftermath

The decision curtailed the Food and Drug Administration's authority over the tobacco industry until Congress enacted specific legislation, prompting legislative responses including later proposals and the 2009 Family Smoking Prevention and Tobacco Control Act enacted by the 111th United States Congress and signed by President Barack Obama. The ruling affected enforcement actions by the FDA, litigation by state attorneys general such as the State of Minnesota and State of Mississippi, and public health campaigns by organizations like the Campaign for Tobacco-Free Kids. Internationally, the decision influenced regulatory strategies in forums such as the World Health Organization and the negotiation of the WHO Framework Convention on Tobacco Control.

Subsequent Developments and Scholarship

Scholars in administrative law, public health law, and regulatory policy analyzed the case in journals including the Harvard Law Review, Yale Law Journal, and New England Journal of Medicine, debating its implications for agency competence, statutory interpretation, and separation of powers. Later jurisprudence and statutory change—most notably the Family Smoking Prevention and Tobacco Control Act—altered the legal landscape by expressly granting the Food and Drug Administration authority over tobacco products, a legislative response to themes in the Court's opinion. Academic commentary assessed the decision alongside cases addressing agency deference such as Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc. and later administrative law developments under the Administrative Procedure Act.

Category:United States Supreme Court cases Category:United States administrative case law Category:Tobacco control